Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 13,300 shares at $22.32 ($297K) on 2024-04-17, disclosed to the SEC on 2024-04-19.
Scheduled sale ($297k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.32 | 6,447 | $144K | 48.4% |
| 2 | $22.32 | 6,447 | $144K | 48.4% |
| 3 | $23.17 | 338 | $8K | 2.6% |
| 4 | $23.97 | 68 | $2K | 0.5% |
| Total | $22.35 avg | 13,300 | $297K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |
| AVTE | SELL | 2023-12-07 | $331K | — | Filing → |